Ligand id: 9175

Name: ripretinib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 88.05
Molecular weight 509.09
XLogP 5.71
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Compound class Synthetic organic
International Nonproprietary Names
INN number INN
10808 ripretinib
DCC-2618 | DCC2618
Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals. It is in clinical development for the treatment of malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors [1]. Another example of a switch control inhibitor is avapritinib.
The chemical structure shown here matches that supplied to the WHO for the INN, and this is claimed in patent WO2010051373 [2] as Example 39. Note that some PubChem SIDs are linked to an incorrect structure (as represented in PubChem CID 46208890).
Database Links
CAS Registry No. 1442472-39-0 (source: PubChem)
GtoPdb PubChem SID 315661258
PubChem CID 71584930
Search Google for chemical match using the InChIKey CEFJVGZHQAGLHS-UHFFFAOYSA-N
Search Google for chemicals with the same backbone CEFJVGZHQAGLHS
Search PubMed clinical trials ripretinib
Search PubMed titles ripretinib
Search PubMed titles/abstracts ripretinib
Search UniChem for chemical match using the InChIKey CEFJVGZHQAGLHS-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone CEFJVGZHQAGLHS